Zoledronic acid increases bone density but does not reduce fractures in frail elderly people, study findsBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1949 (Published 14 April 2015) Cite this as: BMJ 2015;350:h1949
- Zosia Kmietowicz
- 1The BMJ
A single intravenous dose of the osteoporosis drug zoledronic acid has been found to increase bone mineral density in a group of frail elderly women living in nursing homes and long term care facilities, but it did not reduce the incidence of fractures over a two year period.
Researchers from the University of Pittsburgh found that 85% of elderly people in long term care facilities had osteoporosis and fracture rates eight to nine times higher …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial